TL;DRWhy This Matters
For most of the twentieth century, the scientific study of psychedelics was effectively frozen. Substances like LSD, psilocybin, and DMT (dimethyltryptamine) were classified as Schedule I drugs in the United States following the Controlled Substances Act of 1970, a category designating no accepted medical use and high potential for abuse. Whatever promising research had been conducted in the 1950s and 1960s — and there was quite a lot of it — was abruptly shut down. An entire field of inquiry went into a kind of regulatory suspended animation.
What followed those decades of silence was not forgetting — it was underground preservation. Researchers, therapists, philosophers, and spiritual practitioners continued to work with these substances in private, building an experiential literature that the academy could not officially touch. When the research moratorium finally began to lift, in the late 1990s and early 2000s, scientists returned not to a blank slate but to a rich, if unsanctioned, tradition of human inquiry. The convergence of new neuroscience tools, changing cultural attitudes, and an urgent mental health crisis created the conditions for what many now call a psychedelic renaissance.
The stakes are high in multiple directions. Clinically, depression, PTSD, addiction, and end-of-life anxiety represent areas where conventional treatments frequently fail, and early psychedelic research has shown effects that range from promising to genuinely extraordinary. Philosophically, these substances touch the deepest questions humanity has ever asked — about the nature of selfhood, the structure of consciousness, the possibility of meaning, and what happens when ordinary boundaries between self and world dissolve. And spiritually, virtually every human culture that has had access to psychoactive plants or fungi has incorporated them into its most sacred practices. These are not new tools; they are among the oldest.
The thread connecting ancient shamanic ritual, nineteenth-century psychology, and twenty-first-century clinical neuroscience is surprisingly continuous. What changes across the centuries is the vocabulary, the institutional framing, and the methods of investigation — not, apparently, the profundity of the experience itself. Understanding what that experience is, and why it seems to matter so much, is one of the most fascinating intellectual challenges of our time.
The Substances Themselves: A Brief Orientation
Before exploring what these molecules do to the mind, it helps to understand what they are. Psilocybin is a naturally occurring compound found in over two hundred species of fungi, most famously in the genus Psilocybe. When ingested, it is converted in the body to psilocin, which is the active compound. Psilocybin has been used in ritual contexts in Mesoamerica for at least two thousand years — possibly much longer — and was brought to Western scientific attention largely through the work of ethnomycologist R. Gordon Wasson in the late 1950s.
DMT (dimethyltryptamine) is in some ways even more extraordinary. It occurs naturally in dozens of plant species and, according to some researchers, may be produced endogenously in the human brain — though this claim remains scientifically debated. When smoked or vaporized, DMT produces one of the most intense altered states known to pharmacology, typically lasting less than twenty minutes but often described by those who undergo it as subjectively timeless. It is also the psychoactive component of ayahuasca, a ceremonial brew prepared by indigenous Amazonian peoples that combines DMT-containing plants with monoamine oxidase inhibitors, allowing oral activation of the compound. Ayahuasca ceremonies have been practiced in the Amazon basin for centuries — some archaeological evidence suggests millennia — and have more recently become the subject of serious neurobiological investigation.
LSD (lysergic acid diethylamide), synthesized by Albert Hofmann at Sandoz Laboratories in 1938 and accidentally discovered to be psychoactive in 1943, was the compound that first brought psychedelics into the modern Western consciousness. Unlike psilocybin and DMT, it has no traditional ceremonial history, but its effects overlap significantly with both. All three substances belong to the broader pharmacological category of classical psychedelics or serotonergic hallucinogens, meaning they work primarily through agonism at serotonin receptors — particularly the 5-HT2A receptor, whose precise role in consciousness remains an active area of investigation.
Mescaline, found in peyote and San Pedro cacti, and ibogaine, derived from the African shrub Tabernanthe iboga, complete the major classical psychedelics in current research focus, each with deep indigenous ceremonial contexts and distinct pharmacological profiles. The point is not that these substances are interchangeable — they are not — but that they share a family resemblance both chemically and experientially that makes them meaningful to study as a group.
Johns Hopkins and the Return of Rigorous Research
The institution most publicly associated with the contemporary scientific revival of psychedelic research is Johns Hopkins University, specifically its Center for Psychedelic and Consciousness Research, formally established in 2019. This represented the first research center of its kind at a major academic medical institution in the United States, and its founding was treated, rightly, as a significant cultural moment.
The groundwork for that center was laid much earlier, most consequentially in a landmark 2006 study led by Roland Griffiths and colleagues, published in the journal Psychopharmacology. That study administered high-dose psilocybin to healthy volunteers in a controlled, supportive setting and found that a substantial proportion of participants — roughly two-thirds — rated the experience as among the five most spiritually significant of their lives. Some rated it as the single most significant. When participants were followed up fourteen months later, the majority reported persisting increases in well-being, life satisfaction, and what the researchers described as positive behavioral changes. The study used rigorous methodology, including double-blind conditions and active placebos, and it landed in the scientific literature like a stone dropped into still water.
What followed was a gradual accumulation of evidence. Subsequent Johns Hopkins studies investigated psilocybin-assisted therapy for tobacco addiction, finding abstinence rates around eighty percent at six-month follow-up — a result that, if replicated at scale, would represent a transformational development in addiction medicine, where current pharmacological treatments rarely exceed thirty-five percent. Studies on alcohol use disorder, treatment-resistant depression, and major depressive disorder have followed from Hopkins, NYU, Imperial College London, and elsewhere, consistently finding robust effects that outlast the acute drug experience by weeks, months, and in some cases years.
The crucial variable, researchers have found, is not simply the molecule. Set and setting — the internal mental state of the participant and the external environment in which the experience occurs — appear to be major determinants of both the nature and the therapeutic outcome of the experience. This is a finding that indigenous traditions had encoded into ceremonial practice for generations without the vocabulary of clinical psychology. The formal term now used in research protocols is psychedelic-assisted therapy, emphasizing that the substance functions not as a standalone treatment but as a catalyst within a broader therapeutic relationship and structure.
The Default Mode Network and the Neuroscience of Ego Dissolution
How do these substances produce their effects? This is a question that is beginning, at last, to have partial answers — though the complete picture remains far from clear.
The most influential neuroscientific framework for understanding psychedelics centers on the default mode network (DMN), a set of interconnected brain regions that are active when the mind is at rest, engaged in self-referential thought, mental time travel, and the construction of the autobiographical narrative we call the self. The DMN encompasses regions including the medial prefrontal cortex, the posterior cingulate cortex, and the angular gyrus — areas involved in integrating information about who we are, where we've been, and where we're going.
Work by neuroscientist Robin Carhart-Harris and colleagues at Imperial College London, using fMRI and MEG brain imaging, has shown that classical psychedelics reliably suppress activity in the DMN. The degree of this suppression correlates directly with the subjective intensity of the experience — specifically with a phenomenon called ego dissolution, the partial or complete breakdown of the felt sense of being a separate, bounded self. This is one of the most consistently reported and most philosophically charged features of high-dose psychedelic experiences.
When the DMN quiets, activity in other brain regions tends to increase, and — crucially — regions that do not normally communicate begin to do so. Psychedelics appear to increase what researchers call neural entropy, a measure of the complexity and unpredictability of brain activity. Under their influence, the brain operates in a less constrained, more fluid mode, forming connections between areas that ordinarily maintain functional separation. This has led Carhart-Harris to propose the entropic brain hypothesis: that the mind under psychedelics occupies a higher-entropy state than ordinary waking consciousness, one closer to dreaming or early childhood experience than to the organized, prediction-generating machine of the adult brain.
What this means experientially is a dissolution of habitual patterns — perceptual, cognitive, emotional, and self-referential. The rigid narrative structures through which we ordinarily process experience temporarily loosen. This may explain both the therapeutic potential and the profound strangeness of these experiences: the same mechanism that disrupts depressive rumination loops might also allow a person to encounter the world as if for the first time, with a vividness and openness that feels — and may genuinely be — revelatory.
William James, Mystical Experience, and the Long Memory of Philosophy
Long before neuroscience developed the tools to image a dissolving default mode network, philosophers and psychologists were grappling with the same phenomena under different names. The most important early figure in this conversation is William James, the American philosopher and psychologist whose The Varieties of Religious Experience, published in 1902, remains one of the most sophisticated attempts to take mystical experience seriously as a subject of empirical inquiry.
James identified four defining marks of what he called mystical states of consciousness: noetic quality (the sense that genuine knowledge has been received), ineffability (resistance to ordinary language), transiency (brief duration), and passivity (the sense that the experience happens to the person rather than being generated by them). Anyone familiar with accounts of high-dose psychedelic experiences will immediately recognize this phenomenology. The overlap is not coincidental.
James himself experimented with nitrous oxide and was influenced by the philosophical writings of Benjamin Paul Blood, who had written extensively on the mind-altering properties of anesthesia. He did not live to see the synthesis of LSD or the discovery of psilocybin, but he stated explicitly his conviction that "our normal waking consciousness, rational consciousness as we call it, is but one special type of consciousness, whilst all about it, parted from it by the filmiest of screens, there lie potential forms of consciousness entirely different." This sentence reads, over a century later, as almost a précis of the contemporary psychedelic research agenda.
The philosopher Aldous Huxley continued this lineage in his 1954 essay The Doors of Perception, documenting his first mescaline experience and proposing the influential — though debated — reducing valve theory of consciousness: the idea that ordinary brain function acts as a filter, narrowing the totality of possible experience down to the thin stream needed for biological survival, and that psychedelics temporarily open that valve. Huxley's framework drew explicitly on the philosopher Henri Bergson and on the mystical traditions he had spent a lifetime studying. Whether the reducing valve metaphor is neurologically accurate is genuinely uncertain, but it captured something phenomenologically precise that millions of readers recognized.
The continuity from James to Huxley to Griffiths to Carhart-Harris is not merely biographical. It represents a real intellectual lineage: the conviction that altered states of consciousness are not pathologies to be dismissed or curiosities to be catalogued, but data — important, perhaps irreplaceable data — about the nature of mind.
DMT and the Question of Entity Encounters
Of all the phenomena produced by classical psychedelics, none is more puzzling, more culturally persistent, or more philosophically charged than what happens with high-dose DMT. A large proportion of people who undergo high-dose DMT experiences report encountering what they describe as autonomous entities — beings that appear to have independent existence, agency, and intent. These entities communicate, often without words. They are frequently described as more real than ordinary reality, not less. They are loving, terrifying, alien, and familiar simultaneously.
Surveys conducted by researchers at Johns Hopkins — most notably a large-scale study published in 2019 by Alan Davis, Roland Griffiths, and colleagues — found that nearly half of a sample of over two thousand DMT users reported encountering some kind of entity. A substantial portion of those respondents described the encounter as among the most meaningful experiences of their lives, and many reported persisting changes in their beliefs about consciousness, death, and the nature of reality. Remarkably, a significant minority of atheists and agnostics reported that the experience had shifted them toward believing in some form of higher power or fundamental consciousness — not because they were persuaded by argument, but because they felt they had encountered something.
What are these entities? Here the intellectually honest answer is: we do not know. The explanations on offer range across a wide spectrum. At one end of the naturalistic spectrum: they are products of the brain itself, extraordinary creative fictions generated by a mind freed from its ordinary organizational constraints, perhaps drawing on deep archetypal structures. In this view, the entities feel real because the systems that normally distinguish self from other, real from imagined, are temporarily offline. At the other end: they represent genuine contact with non-ordinary dimensions of reality, consistent with the claims of shamanic traditions worldwide who have long insisted that the spirit world is real and navigable.
In between these poles lie numerous intermediate positions. Psychologist Rick Strassman, who conducted the first federally approved clinical research on DMT in the United States in the early 1990s, began his work as a materialist neuroscientist and ended it deeply uncertain. His book DMT: The Spirit Molecule (2001) documents his growing discomfort with purely neurological explanations and his inability to dismiss his participants' reports as simple hallucination. He has since proposed that DMT may function as a kind of endogenous psychedelic produced by the pineal gland, facilitating contact with non-material dimensions — a hypothesis that remains speculative and contested but has proven extraordinarily generative in popular imagination.
The entity encounter question is not merely philosophically interesting in the abstract. It has direct implications for some of the deepest questions in consciousness studies, including the hard problem of consciousness itself: the question of why there is subjective experience at all, and whether it can be fully explained by physical processes.
Indigenous Wisdom and the Ethics of Extraction
Any serious engagement with psychedelics must reckon with the fact that these substances did not enter human experience through laboratory synthesis or clinical trials. They arrived — in most cases — through centuries or millennia of careful, intentional use by indigenous peoples who developed sophisticated frameworks for working with them safely and meaningfully.
Ayahuasca is perhaps the clearest case. The preparation of this brew, combining Banisteriopsis caapi (an MAO inhibitor) with Psychotria viridis (a DMT source) in a synergistic combination that achieves oral psychedelic activity, represents a pharmacological discovery whose sophistication is difficult to explain without crediting the deep observational knowledge of Amazonian peoples. The ceremonial framework surrounding ayahuasca use — including the role of the curandero or vegetalista, the use of icaros (healing songs), the dietary and behavioral restrictions of dieta, and the integration of the experience within a broader cosmological worldview — encodes clinical wisdom that the Western research tradition is only beginning to appreciate.
The same is true of peyote within the Native American Church, the religious tradition that has used peyote sacramentally among Indigenous peoples of North America for well over a century, and in Mesoamerican contexts for far longer. And of psilocybin mushrooms within the Mazatec tradition of Oaxaca, where María Sabina — the healer whose ceremonies R. Gordon Wasson attended and subsequently published about in a Life magazine article in 1957 — practiced a velada (healing ceremony) tradition of considerable complexity and sacredness.
The ethics of this situation are contested and important. Western researchers and entrepreneurs have benefited enormously from knowledge developed and preserved by indigenous communities who have faced legal persecution for using their own traditional medicines within their own cultural frameworks. The ayahuasca tourism industry, centered in cities like Iquitos and the Sacred Valley, has generated economic opportunity in some cases and exploitation and cultural dilution in others. Serious researchers and practitioners in the psychedelic renaissance are increasingly engaging with these concerns — through revenue sharing, explicit acknowledgment of indigenous knowledge, and advocacy for indigenous legal rights — but the tension between scientific appropriation and cultural respect is real and far from resolved.
There is also a deeper epistemological point here. Indigenous traditions do not understand these substances merely as neurochemical tools. They understand them as mediators of relationship with the living world — with plants, animals, ancestors, and the intelligence of nature itself. Whether this cosmological framework is literal, metaphorical, or some third thing that Western conceptual categories cannot quite accommodate is a question that deserves respectful rather than dismissive engagement.
Integration, Risk, and the Limits of the Evidence
The psychedelic renaissance, for all its genuine promise, is not without complications — and intellectual honesty requires taking them seriously.
The first complication is integration: the process of making meaning from, and translating into ordinary life, experiences that are often overwhelming, destabilizing, and resistant to conventional frameworks. Research protocols at Johns Hopkins and elsewhere dedicate significant attention to preparation and integration sessions with trained therapists, and there is growing evidence that this container is not incidental but essential to therapeutic outcomes. But outside clinical trials, many people are using these substances in informal contexts without adequate support structures, and some of them are struggling. Psychedelic experiences can surface trauma, generate intense confusion, and occasionally produce lasting psychological disturbance — particularly in individuals with personal or family histories of psychosis.
Challenging experiences — sometimes called difficult trips, and in their most extreme form, psychedelic-induced psychological emergencies — are real. The research literature is careful to distinguish between challenging experiences that ultimately prove meaningful or even growth-producing and genuinely harmful outcomes. The risk calculus appears favorable for carefully screened participants in supervised settings. It looks different in the absence of that structure.
The second complication is the quality of the evidence base. Much of the clinical research, though genuinely promising, involves small sample sizes, challenges with blinding (it is difficult to conceal whether someone has received a psychedelic or a placebo, since the effects are unmistakable), and short follow-up periods. The field is producing larger studies, and several phase II and phase III clinical trials are underway for MDMA (for PTSD), psilocybin (for depression and addiction), and other compounds. But it remains a young science, and some of the more dramatic claims circulating in popular accounts are ahead of what the data actually support.
Third, there is the growing concern about commercialization. As psychedelic-assisted therapy moves toward mainstream clinical acceptance, significant financial interests have attached themselves to the field. Patent disputes over formulations, therapeutic protocols, and drug delivery mechanisms are emerging. The risk that a healing modality developed over millennia in indigenous communities, refined through decades of underground therapeutic practice, and now validated by academic research could be captured and commodified by pharmaceutical corporations is not hypothetical — it is already underway. This does not invalidate the medicines themselves, but it raises serious questions about who will have access to them, at what cost, and within whose framework.
Consciousness, Meaning, and What Persists
Perhaps the most philosophically significant finding to emerge from the contemporary research is also the most difficult to fully explain: the reliable production of what Griffiths and colleagues describe as mystical-type experiences — unified, deeply felt encounters with what participants consistently describe as ultimate reality, boundless love, or the ground of being — and the correlation of those experiences with lasting positive outcomes.
This finding sits at the intersection of empirical psychology, philosophy of mind, and the ancient questions of every mystical tradition in human history. William James would have recognized it immediately. The medieval Christian mystic Meister Eckhart, the Sufi poet Rumi, the Vedantic philosopher Shankara, the Buddhist teacher Nagarjuna — each of them described states of consciousness that bear a striking phenomenological resemblance to what happens when a carefully prepared person ingests four to five grams of psilocybin mushrooms on a couch with an eye mask and gentle music, in the presence of a trained guide.
What should we make of that resemblance? It could mean that these traditions were inducing similar neurochemical states through different means — meditation, fasting, breathwork, physical ordeal, or community ritual — and that the states themselves, wherever they arise, carry certain invariant features. This is the strong version of the perennial philosophy hypothesis, associated with Huxley, Leibniz, and a long lineage of comparative mystics. It could also mean that the meaning these experiences carry is constructed after the fact, shaped by cultural expectation, and that the neurochemical event itself is just noise filtered through the participant's existing belief system. Or it could mean something more radical: that these states provide genuine access to aspects of reality that are ordinarily inaccessible, and that the consistency across cultures reflects the consistency of whatever those aspects are.
The hard problem of consciousness — David Chalmers' formulation of the question of why physical processes give rise to subjective experience — casts a long shadow over all of this. If we cannot yet explain why there is something it is like to see red, we are nowhere near explaining why there is something it is like to feel that all boundaries between self and cosmos have dissolved, and that what remains is pure luminous awareness. Neuroscience can map the correlates of that experience with increasing precision. Whether those correlates constitute an explanation or merely a description is a question that remains genuinely open.
What psychedelics may have contributed, beyond their clinical applications, is a renewed urgency to take this question seriously. In an intellectual culture that had largely either dismissed consciousness as an epiphenomenon or deferred its investigation indefinitely, the spectacle of serious scientists at Johns Hopkins discussing "the greatest mystery in science" with visible wonder represents something — at minimum — worth paying attention to.
The Questions That Remain
The most honest conclusion to draw from this field is not a set of answers but a set of questions — genuinely unanswered, not merely rhetorical, and likely to occupy researchers, philosophers, and practitioners for generations.
Do DMT entity encounters represent something beyond the brain? The neurological explanation — that the mind, freed from its ordinary filtering and organizational functions, generates extraordinarily vivid autonomous characters from its own unconscious material — is plausible. But it has not been established. The alternative, that these entities have some form of independent existence in dimensions of reality that ordinary consciousness does not access, is extraordinary — but the consistency of reports across cultures, centuries, and individuals is difficult to dismiss entirely. What would it even mean to test this? What methodological approach could distinguish endogenously generated fiction from genuine contact with non-ordinary reality?
How do psychedelic-induced mystical experiences produce lasting change? The correlation between mystical experience scores and therapeutic outcome is robust across multiple studies. But the mechanism is unclear. Does the experience work by disrupting rigid neural patterns, allowing new ones to form? Through the emotional processing that occurs during and after the experience? Through a genuine shift in the framework of meaning within which a person organizes their life? Or through some combination of all three? Understanding the mechanism matters not only scientifically but clinically — it affects how protocols should be designed and what kinds of preparation and integration support actually help.
Is there an endogenous role for DMT in human consciousness? The presence of DMT in human cerebrospinal fluid has been documented, and some researchers have proposed that it is synthesized in the brain itself. If so, what does it do in minute, sub-psychedelic quantities? Could it play a role in dream states, near-death experiences, or spontaneous mystical experiences that occur without any external psychedelic compound? The pineal gland hypothesis associated with Strassman remains speculative, but the broader question of DMT's endogenous function is a legitimate scientific puzzle that remains unresolved.
What is the appropriate relationship between indigenous ceremonial traditions and Western clinical practice? As psychedelic-assisted therapy moves toward regulatory approval and mainstream clinical deployment, the question of how to honor, compensate, and collaborate with the knowledge systems that made this research possible becomes increasingly urgent. What models of benefit-sharing, cultural acknowledgment, and legal protection for indigenous use are both feasible and genuinely just? This is not primarily a scientific question — it is ethical and political — but it is inseparable from any complete account of what this field is and what it owes.
What does the consistency of mystical experience across psychedelics, meditation, near-death states, and spontaneous occurrence tell us about consciousness itself? If a state with certain characteristic features — unity, noetic quality, ineffability, a sense of contact with ultimate reality — can be reliably produced by serotonin agonism, by decades of contemplative practice, by proximity to death, or apparently by certain kinds of spontaneous grace, what does that convergence mean? Is it evidence for the perennial philosophy — the idea that these traditions all describe the same underlying feature of reality? Or is it evidence that the human brain has a particular mode it can enter, and that many roads lead there? And if it is the latter — what is that mode for?
The ancient and the cutting-edge are not as separate as the modern mind tends to assume. When a researcher in a Baltimore laboratory publishes a paper on the neurological correlates of self-dissolution and a Mazatec curandera in Oaxaca prepares mushrooms for a healing ceremony in the same week, they are engaged — from